ETC-216 for coronary artery disease

Stephen J. Nicholls, Kiyoko Uno, Yu Kataoka, Steven E. Nissen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction: Increasing attention has focused on the role of high-density lipoprotein function as a target for cardiprotection. Apolipoprotein A-IMilano (AIM) involves a single amino-acid mutation of the major wild-type protein carried on high-density lipoprotein (HDL) particles. Early evidence of beneficial activities of AIM has stimulated support in its development as a potential therapy to reduce cardiovascular risk. Areas covered: The importance of HDL as a target and early data supporting the beneficial effects of AIM are reviewed. All clinical studies of AIM found in PubMed are reviewed. Expert opinion: ETC-216 represents a lipid-deplete form of HDL containing recombinant AIM. While early evidence suggests that administration of ETC-216 promotes rapid regression of coronary atherosclerosis, bringing this compound to clinical practice will require further trials that evaluate its impact on cardiovascular events.

LanguageEnglish
Pages387-394
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume11
Issue number3
DOIs
Publication statusPublished - 1 Mar 2011

Keywords

  • apoA-I
  • atherosclerosis
  • high-density lipoprotein
  • risk factors

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Nicholls, S. J., Uno, K., Kataoka, Y., & Nissen, S. E. (2011). ETC-216 for coronary artery disease. Expert Opinion on Biological Therapy, 11(3), 387-394. https://doi.org/10.1517/14712598.2011.557061
Nicholls, Stephen J. ; Uno, Kiyoko ; Kataoka, Yu ; Nissen, Steven E. / ETC-216 for coronary artery disease. In: Expert Opinion on Biological Therapy. 2011 ; Vol. 11, No. 3. pp. 387-394.
@article{f8510a5a729c41eebec8b5652f8714f0,
title = "ETC-216 for coronary artery disease",
abstract = "Introduction: Increasing attention has focused on the role of high-density lipoprotein function as a target for cardiprotection. Apolipoprotein A-IMilano (AIM) involves a single amino-acid mutation of the major wild-type protein carried on high-density lipoprotein (HDL) particles. Early evidence of beneficial activities of AIM has stimulated support in its development as a potential therapy to reduce cardiovascular risk. Areas covered: The importance of HDL as a target and early data supporting the beneficial effects of AIM are reviewed. All clinical studies of AIM found in PubMed are reviewed. Expert opinion: ETC-216 represents a lipid-deplete form of HDL containing recombinant AIM. While early evidence suggests that administration of ETC-216 promotes rapid regression of coronary atherosclerosis, bringing this compound to clinical practice will require further trials that evaluate its impact on cardiovascular events.",
keywords = "apoA-I, atherosclerosis, high-density lipoprotein, risk factors",
author = "Nicholls, {Stephen J.} and Kiyoko Uno and Yu Kataoka and Nissen, {Steven E.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1517/14712598.2011.557061",
language = "English",
volume = "11",
pages = "387--394",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "3",

}

Nicholls, SJ, Uno, K, Kataoka, Y & Nissen, SE 2011, 'ETC-216 for coronary artery disease', Expert Opinion on Biological Therapy, vol. 11, no. 3, pp. 387-394. https://doi.org/10.1517/14712598.2011.557061

ETC-216 for coronary artery disease. / Nicholls, Stephen J.; Uno, Kiyoko; Kataoka, Yu; Nissen, Steven E.

In: Expert Opinion on Biological Therapy, Vol. 11, No. 3, 01.03.2011, p. 387-394.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ETC-216 for coronary artery disease

AU - Nicholls, Stephen J.

AU - Uno, Kiyoko

AU - Kataoka, Yu

AU - Nissen, Steven E.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Introduction: Increasing attention has focused on the role of high-density lipoprotein function as a target for cardiprotection. Apolipoprotein A-IMilano (AIM) involves a single amino-acid mutation of the major wild-type protein carried on high-density lipoprotein (HDL) particles. Early evidence of beneficial activities of AIM has stimulated support in its development as a potential therapy to reduce cardiovascular risk. Areas covered: The importance of HDL as a target and early data supporting the beneficial effects of AIM are reviewed. All clinical studies of AIM found in PubMed are reviewed. Expert opinion: ETC-216 represents a lipid-deplete form of HDL containing recombinant AIM. While early evidence suggests that administration of ETC-216 promotes rapid regression of coronary atherosclerosis, bringing this compound to clinical practice will require further trials that evaluate its impact on cardiovascular events.

AB - Introduction: Increasing attention has focused on the role of high-density lipoprotein function as a target for cardiprotection. Apolipoprotein A-IMilano (AIM) involves a single amino-acid mutation of the major wild-type protein carried on high-density lipoprotein (HDL) particles. Early evidence of beneficial activities of AIM has stimulated support in its development as a potential therapy to reduce cardiovascular risk. Areas covered: The importance of HDL as a target and early data supporting the beneficial effects of AIM are reviewed. All clinical studies of AIM found in PubMed are reviewed. Expert opinion: ETC-216 represents a lipid-deplete form of HDL containing recombinant AIM. While early evidence suggests that administration of ETC-216 promotes rapid regression of coronary atherosclerosis, bringing this compound to clinical practice will require further trials that evaluate its impact on cardiovascular events.

KW - apoA-I

KW - atherosclerosis

KW - high-density lipoprotein

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=79851490647&partnerID=8YFLogxK

U2 - 10.1517/14712598.2011.557061

DO - 10.1517/14712598.2011.557061

M3 - Article

VL - 11

SP - 387

EP - 394

JO - Expert Opinion on Biological Therapy

T2 - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 3

ER -